Differences between conventional and nonconventional MRI techniques in Parkinson's disease

Functional Neurology

Volumn 28, Issue 2, 2013, Pages 73-82

  Baglieri, Annalisa ^a   Marino, Maria Adele ^a   Morabito, Rosa ^a   Di Lorenzo, Giuseppe ^a   Bramanti, Placido ^a   Marino, Silvia ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Diffusion tensor imaging; Functional magnetic resonance imaging; High field MRI; Magnetic resonance spectroscopy; Parkinson's disease; volumetric MRI

Indexed keywords

ARTICLE; BOLD SIGNAL; BRAIN ATROPHY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MIDDLE CEREBELLAR PEDUNCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

EID: 84885694515     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: 10.11138/FNeur/2013.28.1.073     Document Type: Article

References (38)

1. Abe K, Terakawa H, Takanashi M, et al (2000). Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull;52:589-595.
2. Adachi M, Hosoya T, Haku T, et al (1999). Evaluation of thesubstantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. AJNR Am J Neuroradiol 20:1500-1506.
3. Barja G (2004). Free radicals and aging. Trends Neurosci 27:595-600.
4. Bohnen NI, Albin RL, Koeppe RA, et al (2006). Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26:1198-1212.
5. Choe BY, Park JW, Lee KS, et al (1998). Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol 33:450-455.
6. Dexter DT, Wells FR, Lees AJ, et al (1989). Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836.
7. Di Napoli M, Shah IM, Stewart DA (2007). Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Rev Neurother 7:1693-1729.
8. Gama RL, Távora DF, Bomfim RC, et al (2010). Morphometry MRI in the differential diagnosis of parkinsonian syndromes. Arq Neuropsiquiatr 68:333-338.
9. Gattellaro G, Minati L, Grisoli M, et al (2009). White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 30:1222-1226.
10. Geng DY, Li YX, Zee CS (2006). Magnetic resonance imagingbased volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery 58:256-262.
11. Gorell JM, Ordidge RJ, Brown GG, et al (1995). Increased ironrelated MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45:1138-1143.
12. Graham JM, Paley MN, Grünewald RA, et al (2000). Brain iron deposition in Parkinson's disease imaPRIME magnetic resonance sequence. Brain 123:2423-2431.
13. Greffard S, Verny M, Bonnet AM, et al (2006). Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63:584-588.
14. Griffith HR, Okonkwo OC, O'Brien T, et al (2008). Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed 21:381-387.
15. Guevara CA, Blain CR, Stahl D, et al (2010). Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol 17:1193-1202.
16. Hattingen E, Magerkurth J, Pilatus U, et al (2009). Phosphorus and proton magnetic resonance spectroscopy demonstratesmitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132:3285-3297.
17. Heerschap A, Zijlmans J, de Koster A, et al (1993). Metabolite levels at three brain locations in parkinsonism as viewed by proton MRS. SMRM, 12th Annual Meeting. New York: 234.
18. Jellinger KA, Seppi K, Wenning GK, et al (2002). Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109:329-339.
19. Lucetti C, Del Dotto P, Gambaccini G, et al (2007). Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Mov Disord 22:2170-2175.
20. Marek K, Jennings D (2009). Can we image premotor Parkinson disease? Neurology 72:S21-S26.
21. Martin WR (2009). Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat Disord 15:S215-218.
22. Martin WR, Wieler M, Gee M, et al (2009). Temporal lobe changes in early, untreated Parkinson's disease. Mov Disord 24:1949-1954.
23. Menke RA, Scholz J, Miller KL, et al (2009). MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 47:435-441.
24. Nandhagopal R, McKeown MJ, Jon Stoessl A (2008). Functional imaging in Parkinson disease. Neurology 70:1478-1488.
25. Oikawa H, Sasaki M, Tamakawa Y, et al (2002). The substantia nigra in Parkinson disease: proton density-weighted spinecho and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 23:1747-1756.
26. O'Neill J, Schuff N, Marks WJ Jr, et al (2002). Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 17:917-927.
27. Péran P, Luccichenti G, Cherubini A, et al (2006). High-field neuroimaging in Parkinson's disease. In: Salvolini U, Scarabino T (Eds) High Field Brain MRI, Use in Clinical Practice. Berlin, Heidelberg, Springer-Verlag:194-200.
28. Péran P, Cardebat D, Cherubini A, et al (2009). Object naming and action-verb generation in Parkinson's disease: a fMRI study. Cortex 45:960-971.
29. Pujol J, Junqué C, Vendrell P, et al (1992). Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch Neurol 49:1119-1122.
30. Quattrone A, Nicoletti G, Messina D, et al (2008). MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246:214-221.
31. Sabatini U, Boulanouar K, Fabre N, et al (2000). Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 123:394-403.
32. Schapira AH (2006). Etiology of Parkinson's disease. Neurology 66:S10-23.
33. Schrag A, Good CD, Miskiel K, et al (2000). Differentation of atypical parkinsonian syndrome with routine MRI. Neurology 54:697-702.
34. Schuff N (2006). Potential role of high-field MRI for studies in Parkinson's disease. Mov Disord;24:S684-S690.
35. Taylor KC, Counsell C (2006) Is it Parkinson's disease, and if not, what is it? Pract Neurol 6:154-165.
36. Weintraub D, Comella CL, Horn S (2008). Parkinson's diseasepart 1: pathophysiology, symptoms, burden, diagnosis and assessment. Am J Manag Care 14:S40-48.
37. Zhan W, Kang GA, Glass GA, et al (2012). Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord 27: 90-97.
38. Zijlmans JC (2010). The role of imaging in the diagnosis of vascular parkinsonism. Neuroimaging Clin N Am 20:69-76.